Atrasentan
- Generic Name
- Atrasentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H38N2O6
- CAS Number
- 173937-91-2
- Unique Ingredient Identifier
- V6D7VK2215
- Background
Atrasentan is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists. It is a novel, selective endothelin A receptor antagonist (SERA).
- Indication
Investigated for use/treatment in prostate cancer and cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00017264
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath